Table 5.
Differences in cost and health outcome per 100 000 women for the base‐case strategies (high risk of spontaneous preterm delivery (sPTD) indicated by sonographic cervical length (CL) ≤ 25 mm) in comparison with the ‘No screening’ strategy, according to CL screening at 18 + 0 to 20 + 6 weeks (Cx1) and at 21 + 0 to 23 + 6 weeks (Cx2)
| Strategy | Difference in cost compared with ‘No screening’ | Difference in health outcomes compared with ‘No screening’ | ||
|---|---|---|---|---|
| Screening year (USD) | Lifetime (USD) | Screening‐year mortality (n) | Lifetime QALYs (n) | |
| CL screening at Cx1 | ||||
| No screening, treat high‐risk group | –1 201 000 | –2 630 000 | –2.1 | + 71 |
| Universal screening | 5 894 000 | 3 327 000 | –4.0 | + 136 |
| Low‐risk‐based screening | 4 425 000 | 449 000 | –6.0 | + 206 |
| Nullipara screening | 1 426 000 | –1 454 000 | –4.3 | + 148 |
| CL screening at Cx2 | ||||
| No screening, treat high‐risk group | –832 000 | –2 124 000 | –1.8 | + 64 |
| Universal screening | 10 870 000 | 8 154 000 | –4.1 | + 141 |
| High‐risk‐based screening | 632 000 | –491 000 | –1.7 | + 58 |
| Low‐risk‐based screening | 10 234 000 | 6 663 000 | –5.3 | + 181 |
| Nullipara screening | 5 232 000 | 2 750 000 | –3.6 | + 124 |
QALYs, quality‐adjusted life years; USD, US dollar.